アブストラクト
| Title | 視神経脊髄炎 |
|---|---|
| Subtitle | 特集 神経難病の今 〜疫学・成因・治療の研究最前線〜 |
| Authors | 清水文崇 |
| Authors (kana) | |
| Organization | 山口大学医学部附属病院脳神経内科 |
| Journal | Pharma Medica |
| Volume | 39 |
| Number | 3 |
| Page | 29-32 |
| Year/Month | 2021 / 3 |
| Article | 報告 |
| Publisher | メディカルレビュー社 |
| Abstract | 「はじめに」 視神経脊髄炎(neuromyelitis optica: NMO)は視神経と脊髄を炎症の主座とする自己免疫性中枢神経疾患であり, 以前からDevic病と呼ばれて多発性硬化症(multiple sclerosis: MS)の亜型と考えられてきた. しかし, アクアポリン4(aquaporin 4: AQP4)抗体の発見により病態解明が進み, NMOは自己免疫性アストロサイト病という, MSとは異なる新しい疾患概念であると考えられるようになった. さらに症例が蓄積され, AQP4抗体が陽性で視神経炎か脊髄炎のどちらかのみ単独しかない症例や, 視神経炎や脊髄炎が確認できず大脳病変のみ認める症例が存在することが明らかとなり, それらも含めてAQP4抗体陽性となる1つのスペクトルの自己免疫疾患として, NMO spectrum disorder (NMOSD)という病名が使われるようになった. |
| Practice | 薬学 |
| Keywords | 視神経脊髄炎, 疫学, 成因, 診断, 治療 |
- 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
参考文献
- 1) Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85: 177-89.
- 2) Miyamoto K, Fujihara K, Kira JI, et al. Nationwide epidemiological study of neuromyelitis optica in Japan. J Neurol Neurosurg Psychiatry. 2018; 89: 667-8.
- 3) Estrada K, Whelan CW, Zhao F, et al. A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica. Nat Commun. 2018; 9: 1929.
- 4) Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364: 2106-12.
- 5) Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202: 473-7.
残りの12件を表示する
- 6) Hinson SR, Romero MF, Popescu BF, et al. Molecular outcomes of neuromyelitis optica(NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci USA. 2012; 109: 1245-50.
- 7) Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain. 2007; 130: 1224-34.
- 8) Misu T, Takano R, Fujihara K, et al. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry. 2009; 80: 575-7.
- 9) Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009; 66: 630-43.
- 10) Shimizu F, Schaller KL, Owens GP, et al. Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. Sci Transl Med. 2017; 9: pii: eaai9111.
- 11) Shimizu F, Takeshita Y, Hamamoto Y, et al. GRP 78 antibodies are associated with clinical phenotype in neuromyelitis optica. Ann Clin Transl Neurol. 2019; 6: 2079-87.
- 12) Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014; 82: 474-81.
- 13) Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018; 89: 346-51.
- 14) Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica(Devic's syndrome). Neurology. 1999; 53: 1107-14.
- 15) Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler. 2007; 13: 968-74.
- 16) Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019; 381: 614-25.
- 17) Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019; 381: 2114-24.
